Title:
CRYSTALLINE FORMS OF BRUTON TYROSINE KINASE INHIBITOR
Document Type and Number:
Japanese Patent JP2023162162
Kind Code:
A
Abstract:
To provide crystalline forms of a Bruton tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, and preparation methods thereof.SOLUTION: A crystalline form has an X-ray powder diffraction (XRPD) pattern with characteristic peaks at 7.0±0.1° 2-Theta, 14.0±0.1° 2-Theta, 15.7±0.1° 2-Theta, 18.2±0.1° 2-Theta, 19.1±0.1° 2-Theta, 19.5±0.1° 2-Theta, 20.3±0.1° 2-Theta, 22.1±0.1° 2-Theta, and 22.9±0.1° 2-Theta.SELECTED DRAWING: Figure 1
Inventors:
MARK SMYTH
ERICK GOLDMAN
DAVID D WIRTH
NORBERT PURRO
ERICK GOLDMAN
DAVID D WIRTH
NORBERT PURRO
Application Number:
JP2023115449A
Publication Date:
November 08, 2023
Filing Date:
July 13, 2023
Export Citation:
Assignee:
PHARMACYLICS LLC
International Classes:
C07D487/04; A61K9/48; A61K31/519; A61K47/02; A61K47/10; A61K47/12; A61K47/14; A61K47/20; A61K47/26; A61K47/32; A61K47/34; A61K47/36; A61K47/38; A61K47/42; A61P35/00; A61P35/02
Attorney, Agent or Firm:
Kiyohara International Patent Office
Previous Patent: artificial intelligence system
Next Patent: How to reduce side effects of anti-CD30 antibody drug conjugate therapy
Next Patent: How to reduce side effects of anti-CD30 antibody drug conjugate therapy